Sucralfate tablets recalled because bankruptcy left the quality program unmonitored
Sucralfate Tablets USP 1 gram from Nostrum Laboratories are being recalled across all lots within expiry because the firm cannot monitor its quality program after filing for Chapter 11. 60,608 bottles affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall arising from an inability to assure quality rather than any defect found in the product itself.
Plain-English summary
Sucralfate Tablets, USP 1 gram, packaged in 100-count bottles (NDC 29033-0003-01) and 500-count bottles (NDC 29033-0003-05), prescription only, manufactured by Nostrum Laboratories, Inc. of Kansas City, Missouri, are being recalled across all lots within expiry dates. The action covers 60,608 bottles.
The stated reason is CGMP deviations: the recalling firm filed for Chapter 11 in September 2024, and as a result it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality and purity characteristics they are purported or represented to possess, rendering the products adulterated. The FDA classified the action as Class II. The source does not report any specific defect having been found in the product.
Distribution was nationwide within the United States.
Patients holding affected product should speak to their pharmacist or prescriber before stopping treatment, and pharmacies should follow the instructions issued by the manufacturer.
The recalled product
- Product
- Sucralfate Tablets, USP 1 gram, packaged in a) 100-count bottles NDC 29033-0003-01, and b) 500-count bottles, NDC 29033-0003-05), Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120.
- Manufacturer
- Nostrum Laboratories, Inc.
- Category
- Drug — Oral tablet
- Affected units
- 60,608
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots within expiry dates.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Nostrum Laboratories, Inc.
See all →- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- ModerateNostrum Recalls Theophylline Tablets Due to Incorrect Lot and Expiration Dates
FDA (Drugs) · 2020-04-01
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19